Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)

Iris Y. Sheng; Megan Kruse; Kathryn M. Leininger; Moshe C. Ornstein

doi:10.1155/2019/6246209

Case Reports in Oncological Medicine (Jan 2019)

Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)

Iris Y. Sheng,
Megan Kruse,
Kathryn M. Leininger,
Moshe C. Ornstein

Affiliations

Iris Y. Sheng: Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
Megan Kruse: Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
Kathryn M. Leininger: Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
Moshe C. Ornstein: Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA

DOI: https://doi.org/10.1155/2019/6246209
Journal volume & issue: Vol. 2019

Abstract

Read online

Synchronous tumors are defined as two tumors arising concurrently or within six months of each other. Reports of synchronous RCC and breast cancer are limited to nonmetastatic renal cell carcinoma (RCC) and hormone receptor-positive infiltrative ductal carcinoma. We present the first case of synchronous metastatic renal cell carcinoma and metastatic triple-negative breast cancer, managed with a novel combination of immunotherapy and chemotherapy.

Published in Case Reports in Oncological Medicine

ISSN: 2090-6706 (Print); 2090-6714 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://onlinelibrary.wiley.com/journal/7583

About the journal